Integra Lifesciences Holdings Corp(IART) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | RUT | P/E | 74.41 | EPS (ttm) | 0.16 | Insider Own | 14.48% | Shs Outstand | 77.8M | Perf Week | 3.38% |
| Market Cap | 0.95B | Forward P/E | 5.13 | EPS next Y | 1.88% | Insider Trans | - | Shs Float | 66.5M | Perf Month | -26.44% |
| Enterprise Value | 2.64B | PEG | 1.48 | EPS next Q | 0.64 | Inst Own | 94.83% | Short Float | 11% | Perf Quarter | -28.5% |
| Income | 0.01B | P/S | 0.57 | EPS this Y | 5.12% | Inst Trans | -1.27% | Short Ratio | 7.53 | Perf Half Y | 21.43% |
| Sales | 1.66B | P/B | 0.89 | EPS next 5Y | 3.46% | ROA | 0.36% | Short Interest | 7.32M | Perf YTD | -1.45% |
| Book/sh | 13.71 | P/C | 3.05 | EPS past 3/5Y | - | ROE | 1.24% | 52W High | -40.26% ($20.49) | Perf Year | -21.34% |
| Cash/sh | 4.01 | P/FCF | 11.1 | Sales past 3/5Y | 1.63% 3.57% | ROIC | 0.43% | 52W Low | 40.69% ($8.70) | Perf 3Y | -64.22% |
| Dividend Est. | - | EV/EBITDA | 7.63 | EPS Y/Y TTM | 102.6% | Gross Margin | 54.85% | Volatility(W/M) | 4.16% 5.49% | Perf 5Y | -81.73% |
| Dividend TTM | - | EV/Sales | 1.6 | Sales Y/Y TTM | 0.84% | Oper. Margin | 11.63% | ATR (14) | 0.72 | Perf 10Y | -70.03% |
| Dividend Ex-Date | - | Quick Ratio | 2.21 | EPS Q/Q | 368.47% | Profit Margin | 0.79% | RSI (14) | 37.28 | Recom | 2.75 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.62 | Sales Q/Q | 2.27% | SMA20 | -6.62% ($13.11) | Beta | 1.26 | Target Price | $15.67 |
| Payout | - | Debt/Eq | 1.88 | Earnings | 2026/10/21 | SMA50 | -18.4% ($15) | Rel Volume | 1.84 | Prev Close | $11.99 |
| Employees | 4427 | LT Debt/Eq | 1.82 | EPS/Sales Surpr. | 5.85% -0.48% | SMA200 | -12.95% ($14.06) | Avg Volume(3M) | 0.97M | Price | $12.24 |
| IPO | 1995/8/16 | Option/Short | Yes/Yes | Trades | 13705 | Volume | 1,789,057 | Change | 2.09% |
🧠 Integra LifeSciences (IART) is a U.S. medical device company whose core focus lies in neurosurgical technologies and regenerative medicine-based tissue repair. Its business is organized into two segments covering neurosurgical specialties—such as instruments for brain surgery, intracranial pressure monitoring, and dural repair grafts—and complex wound care along with peripheral nerve repair. The company is regarded as a niche leader with a sharp focus on specialty surgical areas.
Over the past 1 year, roughly in the middle
40% below its 1-year high.
Traded more than usual. That is 184% of its average volume.
IART earns at a steady pace
Of every $100 in sales, $11.63 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +5.1% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $763. Peers typically go for $1,165. Compared with its own 3-year average, it is 156% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -81.7%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 94.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #46 of 142 in the industry
Based on market cap of $952M.
SIBN#43 SI-BONE Inc $978M PER - 
BBNX#44 Beta Bionics Inc $963M PER - 
QDEL#45 QuidelOrtho Corp $961M PER - IART#46 Integra Lifesciences Holdings Corp $952M PER 74.4 
PACB#47 Pacific Biosciences of California Inc $880M PER - 
FAQ
What kind of company is IART?
IART belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of IART?
The market cap of IART is approximately $952M, ranking 2,623 within its sector.
What is the P/E ratio of IART?
IART has a P/E ratio of approximately 74.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for IART?
IART has recorded a 52-week high of $20.49 and a low of $8.70.
